Resolvin E1 as a novel agent for the treatment of asthma
Authors:
- 15 April 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Targets
- Vol. 13 (5) , 513-522
Abstract
(2009). Resolvin E1 as a novel agent for the treatment of asthma. Expert Opinion on Therapeutic Targets: Vol. 13, No. 5, pp. 513-522. doi: 10.1517/14728220902865622Keywords
This publication has 81 references indexed in Scilit:
- Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actionsJournal of Experimental Medicine, 2008
- The cytokine network in asthma and chronic obstructive pulmonary diseaseJournal of Clinical Investigation, 2008
- Airway Lipoxin A4 Generation and Lipoxin A4 Receptor Expression Are Decreased in Severe AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Resolvin E1 regulates interleukin 23, interferon-γ and lipoxin A4 to promote the resolution of allergic airway inflammationNature Immunology, 2008
- Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediatorsNature Reviews Immunology, 2008
- Synthetic chemerin-derived peptides suppress inflammation through ChemR23Journal of Experimental Medicine, 2008
- Lipoxin A 4 stable analogs reduce allergic airway responses via mechanisms distinct from CysLT1 receptor antagonismThe FASEB Journal, 2007
- Resolvin E1 and protectin D1 activate inflammation-resolution programmesNature, 2007
- Resolution of in flammation: state of the art, definitions and termsThe FASEB Journal, 2007
- Resolution of inflammation: the beginning programs the endNature Immunology, 2005